Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.
In this podcast, Cancer.Net Associate Editors share exciting research from the ASCO20 Virtual Scientific Program.
Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.
Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.
In the first podcast of the Clinical Trials in Genitourinary Cancers series, experts discuss 3 clinical trials that are currently exploring new ways of treating kidney, bladder, and prostate cancers.
Dr. Ricardo Cubedo describes 3 research highlights from the ESMO 2019 Congress, including targeted therapy for ovarian cancer, immunotherapy for lung cancer, and more study data on targeted tumor-agnostic treatment.
Learn how tumor marker tests can help doctors diagnose cancer and plan the best possible treatment plan for each person.
Cancer.Net Associate Editors explain research presented at the 2019 ASCO Annual Meeting, including new research in colon cancer, gastric cancer, pancreatic cancer, and leukemia.
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.
